2024-517988-23-00招募中1 期
C6081001: A Phase 1 Study of PF-07985045 in Participants with Advanced Solid Tumors
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- Pfizer Inc.
- 入组人数
- 61
- 试验地点
- 4
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Clinical Medical Lead
Scientific
Pfizer Inc.
研究点 (4)
Loading locations...
相似试验
招募中
不适用
A Phase I/II Study of CG200745 PPA to Determine the Maximum Tolerated Dose and Evaluate the Safety and Efficacy in Patients with Myelodysplastic Syndrome (MDS) Who Failed to Respond to Prior Hypomethylating TherapyDiseases of the blood and blood -forming organs and certain disorders involving the immune mechanismKCT0002194CrystalGenomics18
已完成
不适用
An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects with Advanced Malignancies and Varying Degrees of Hepatic ImpairmentNL-OMON41294Onyx Therapeutics, Inc.5
撤回
不适用
A Phase I, open-label study to investigate the pharmacokinetics of GLPG2451 given as two doses of a capsule formulation in healthy subjectsCystic fibrosismucoviscidosisNL-OMON45502Galapagos SAS12
进行中（未招募）
不适用
AN OPEN-LABEL, RANDOMISED PHASE 1B/2 STUDY OF PF-04691502 IN COMBINATION WITH LETROZOLE COMPARED WITH LETROZOLE ALONE IN PATIENTS WITH ESTROGEN RECEPTOR POSITIVE, HER-2 NEGATIVE EARLY BREAST CANCERESTROGEN RECEPTOR POSITIVE, HER-2 NEGATIVE EARLY BREAST CANCER WITH KI-67 HIGHER THAN 10%MedDRA version: 15.0Level: LLTClassification code 10070575Term: Estrogen receptor positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-003044-53-SEPfizer Inc., 235 East 42nd Street, New York, NY 10017166
进行中（未招募）
1 期
AN OPEN-LABEL, RANDOMISED PHASE 1B/2 STUDY OF PF-04691502 IN COMBINATION WITH LETROZOLE COMPARED WITH LETROZOLE ALONE IN PATIENTS WITH ESTROGEN RECEPTOR POSITIVE, HER-2 NEGATIVE EARLY BREAST CANCEREUCTR2011-003044-53-ESPfizer, S.L.U.220